A Discussion of the CDMO Strategies
Hear directly from Joerg Ahlgrimm, CEO of SK pharmteco, in this Pharmaceutical Technology video interview from DCAT Week 2026, where he discusses the company’s three-business-unit strategy, growth in cell and gene therapy, and the future of global CDMO operations.
Integrated Expertise Across Three Strategic Business Units
SK pharmteco brings together specialized capabilities across three core areas:
- Small Molecules
Advance your program with experienced development and manufacturing support for APIs and other complex small-molecule needs.
- Peptides
Work with a team equipped to support peptide development and manufacturing with quality, flexibility, and speed.
- Viral Vectors
Accelerate cell and gene therapy programs with viral vector capabilities designed to support innovation from development through production.
Watch the interview to learn how SK pharmteco is building a globally connected CDMO platform for the next generation of therapies.
Read the related press release HERE.
What is the SK pharmteco interview about?
The interview covers SK pharmteco’s three-business-unit strategy focused on small molecules, peptides, and viral vectors, along with its outlook on cell and gene therapy, AI, and global supply chains.
Where was the interview done?
The Pharmaceutical Technology video is presented as part of DCAT coverage on the source page.
Who should watch the interview?
Procurement leaders, project managers, researchers, operations teams, and executives at pharmaceutical, biotech, and related organizations evaluating CDMO partners.